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Abstract 
Nonribosomal peptides are products that fall into the class of secondary metabolites with a diverse properties as 
toxins, siderophores, pigments, or antibiotics, among others. Unlike other proteins, its biosynthesis is independent 
of ribosomal machinery. Nonribosomal peptides are synthesized on large nonribosomal peptide synthetase (NRPS) 
enzyme complexes. NRPSs are defined as multimodular enzymes, consisting of repeated modules. The NRPS enzymes 
are at operons and their regulation can be positive or negative at transcriptional or post‑translational level. The pres‑
ence of NRPS enzymes has been reported in the three domains of life, being prevalent in bacteria. Nonribosomal pep‑
tides are use in human medicine, crop protection, or environment restoration; and their use as commercial products 
has been approved by the U. S Food and Drug Administration (FDA) and the U. S. Environmental Protection Agency 
(EPA). The key features of nonribosomal peptides and NRPS enzymes, and some of their applications in industry are 
summarized.
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Background
Nonribosomal peptides is a diverse family of natural 
products fall into the class of secondary metabolites with 
a diverse properties as toxins, siderophores, pigments, 
antibiotics, cytostatics, immunosuppressants or antican-
cer agents [1, 2]; and have a particularity: their synthesis 
is independent of ribosomal machinery. Soil-inhabiting 
microorganisms, such as Actinomycetes and Bacilli, and 
eukaryotic filamentous fungi are mostly producers of 
nonribosomal peptides, but marine microorganisms have 
also emerged as a source for such peptides [3]. These 
peptides have a structural features such as contain amino 
acids like ornithine or imino acids, and their structures 
are macrocyclic, branched macrocyclic, dimers or trim-
ers of identical structural elements [4]. Usually nonribo-
somal peptides are synthesized on large nonribosomal 
peptide synthetase (NRPS) enzyme complexes, defined as 
modular multidomain enzymes; nevertheless more than 
half of the NRPS enzymes found in a genome-mining 
study of 2699 genomes by Wang et al. [1] are nonmodular 
NRPS enzymes. Nonmodular NRPS enzymes are found 
in siderophore biosynthetic pathways like EntE and 
VibH in enterobactin, and VibE in vibriobactin [5] or as 
a stand-alone peptidyl carrier protein such as BlmI from 
the bleomycin gene cluster [6]. The presence of NRPS 
enzymes has been reported in the three domains of life, 
being prevalent in bacteria, less frequent in eukarya and 
rare in archaea. Within bacteria domain, Proteobacteria, 
Actinobacteria, Firmicutes, and Cyanobacteria were the 
phyla with major abundance of these enzymes, and there 
has been observed a correlation between genome size 
and the number of NRPS’s clusters [1]. The key features 
of the microbial biosynthesis of nonribosomal peptides, 
the structure and regulation of NRPS enzymes, and some 
applications in industry are summarized below.
Biosynthesis of nonribosomal peptides
The biosynthesis of nonribosomal peptides is done by 
NRPSs which are modularly organized multi-enzyme 
complexes which serve as templates and biosynthetic 
machinery, via a thiotemplate mechanism independent 
of ribosomes [2]. A module is defined as a section of the 
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NRPS enzyme that incorporate in a specific manner one 
amino acid into the peptide backbone, and in turn the 
modules can be divided into domains, which catalyze 
the individual steps of nonribosomal peptide synthe-
sis. Each module consist of three domains, adenylation 
(A) domain, peptidyl carrier protein (PCP) or thiolation 
(T) domain, and condensation (C) domain which carry 
out the synthesis of nonribosomal peptides (Fig.  1) [7]. 
The order of modules is usually co-linear to the product 
peptide sequences [8, 9]. Nonribosomal peptides syn-
thesis proceeds in a N- to C-terminal direction, produc-
ing peptides that are usually about 3–15 amino acids in 
length, and the released peptides can be linear, cyclic, or 
branched-cyclic [3]. There is a sequence motif conserved 
in domains that facilitates the identification of these 
using sequences search tools like BLAST, as in the study 
done by Etchegaray et al. [10] to identified NRPSs in the 
genome of Xanthomonas axonopodis and X. campestri. 
The first step in the biosynthesis is done by the A-domain, 
which recognizes and performs activation of amino acid 
substrate via adenylation using Mg-ATP, result in an ami-
noacyl adenylated intermediate [11]. The A-domain con-
sist of ~550 amino acids, and has ten amino acid residues 
that can be considered as the “codons” of NRPS enzymes 
and are important to substrate specificity [12]. The sub-
strates that can be recognized by A-domain can include 
D and L forms of the 20 amino acids used in ribosomal 
proteins synthesis, as well as non-proteino-genic amino 
acids such as ornithine, imino acids, and hydroxy acids 
such as α-aminoadipic and β-butyric acids [2]. The reac-
tion carried out by the A-domain shares the same chem-
istry as that performed by aminoacyl-tRNA synthetases 
(AARSs), which act in the initial step of ribosome-driven 
protein synthesis [8, 13]. The second step is performs by 
the PCP-domain of  ~80 amino acids [12], which cova-
lently binds the activated amino acid to their cofactor 
4′-phosphopantetheine (PP) arm via a thioester bond and 
transfer the activated substrate and the elongation inter-
mediates to C-domain [14]. The final step is carried out 
by the C-domain of  ~450 amino acids, which catalyzes 
peptide bond formation between the carboxyl group of 
the nascent peptide and the amino acid carried by the 
flanking module, allowing the translocation of the grow-
ing chain to the following module [12, 13]. After conden-
sation step, the linear intermediate peptide is release with 
the help of thioesterase (TE) domain by either hydrolysis 
Fig. 1 Structural features of nonribosomal peptide synthetase enzymes. Nonribosomal peptide synthetase enzymes can be subdivided in modules, 
each incorporating one amino acid. Each module consist of three domains: adenylation (A) domain, peptidyl carrier protein (PCP) domain, and 
condensation (C) domain, which carry out the synthesis of nonribosomal peptides; the epimerization (E) domain and thioesterase (TE) domain is 
also represents. In this figure, surfactin biosynthesis was exemplified
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or internal cyclization in bacterias, and less frequent in 
NRPSs of fungi. In fungi the chain release is carried out 
by a variety of mechanisms, two of which are (1) a termi-
nal C domain, which catalyzes release by inter- or intra-
molecular amide bond formation, and (2) a thioesterase 
NADP(H) dependent reductase (R) domain which cata-
lyzes reduction with NADPH to form an aldehyde [2]. 
The primary product of this synthesis may be post-syn-
thetically modified to achieve its mature form by addi-
tional tailoring enzymes which are not part of NRPS by 
N-, C- and O-methylation, glycosylation, hydroxylation, 
acylation, halogenation or heterocyclic ring formation [3, 
15, 16]. These tailoring enzymes and their reactions con-
tribute to generate the structural diversity of nonriboso-
mal peptides [10].
Structure of nonribosomal peptide synthetase 
(NRPS) enzymes
NRPSs are defined as multimodular enzymes, consisting 
of repeated modules with A-PCP-C domains [17]. Multi-
modular NRPS proteins are frequently in fungal genomes 
[3], and all modules that participate in the assembly of a 
peptide are connected within a single enzyme [10]. Tan-
dem duplication and recombination is may be the origin 
of modules of multimodular NRPS enzymes, as in the 
case of SimA (Cyclosporin synthetase) enzyme of Toly-
pocladium inflatum and Enniatin synthetase of Fusarium 
equiseti, respectively [2]. Nevertheless, more than half 
of the NRPS enzymes finding in a genome-mining study 
of 2699 genomes are nonmodular NRPS enzymes, being 
common in bacterial systems where they are organized in 
clusters [1, 3, 10]. Nonmodular NRPS enzymes consist-
ing of one or two A-PCP-C modules, or lacked complete 
A-PCP-C modules and consist of a single A-domain or an 
A-PCP unit followed by a variety of C-terminal domains 
[2]. In bacterial systems, mono or bi modular NRPSs can 
interact with others NRPS proteins and performs biosyn-
thesis by first activating the amino acid and then trans-
ferred the activated substrate either to a C domain in the 
same NRPS or in a different NRPS, known as nonlinear 
biosynthesis [3]. Taxonomic distributions of mono/bi 
modular NRPS subfamilies suggest an ancient origin, 
possibly predating the divergence of eubacteria and fungi 
[2]. There is third structure of NRPSs which is fused to a 
polyketide synthase (PKS) unit, both types of synthetases 
are fused in a single polypeptide [10]. Of 3339 gene clus-
ters encoding NRPS and PKS found by Wang et  al. [1], 
one-third (1147) of gene clusters belonged to the hybrid 
type and encoded 462 hybrid proteins that contain both 
NRPS and PKS core domains. PKSs are large megasyn-
thases related to fatty acid synthases, that biosynthesize 
small molecule polyketides with diverse natural function 
as nonribosomal peptides [2].
Regulation of NRPS genes
Global regulators such as DegU and Comp/ComA two-
component system can act at transcriptional level, 
regulating positively the expression of srfA, bac, and 
bmy cluster genes of Bacillus spp., which encodes sur-
factin (Fig.  1), bacilysin and bacillomycin, respectively 
[18–20]. In the case of srfA genes that encoding for the 
surfactin, the transcriptional initiation is through ComX 
pheromone that can activated ComP, causing ComP to 
autophosphorylate and, subsequently, donate a phos-
phate group to ComA. Upstream of the srfA promoter 
there are ComA boxes, which are recognized by phos-
phorylated ComA and binding to them as a tetramer 
initializing the transcription of srfA [18, 19, 21]. Another 
positive regulator of transcription of srfA is PerR protein, 
which positively modulates srfA expression by binding to 
regions located upstream of ComA boxes, known as PerR 
boxes [22]. Expression of the bac operon is dependent on 
a σA-dependent promoter, which is activated by interac-
tion with DegU at the final stage of vegetative growth. 
Binding of DegU to the bac operon promoter occurred 
mainly at three sites, in a similar way that occur with bmy 
operon, in which DegU binds directly to two sites located 
upstream of the bacillomycin D promoter [20, 23]. In the 
opposite case, a down-regulation is exerted on the bac 
operon through ScoC protein, which binds at the bac 
promoter sequence in ScoC boxes located between posi-
tions −50 and −42 (ScoC box1) and between positions 
−12 and −4 (ScoC box2) [24]. While srfA is repressed by 
CodY at high concentrations of amino acids Ile, Leu, and 
Val. AbrB and Spx are two other negative regulators that 
turn off the transcription of srfA genes [19]. In the case 
of SrfA NRPS enzyme, is necessary a post-translational 
modification to become active; 4′-phosphopantetheinyl 
transferase (Sfp/PPTase) is required for the activation 
of SrfA enzymes by converting the inactive apo-forms 
to active holo-forms [25]. In the case of Streptomyces 
peucetius, the biosynthesis of non-ribosomal peptide 
doxorubicin, an antitumor drugs, is up regulated by the 
networking of transcriptional regulators dnrO, dnrN, and 
dnrI. The product of dnrO gene binds to the dnrN/dnrO 
promoter region and activates dnrN. DnrN activates the 
transcription of dnrI gene and, DnrI activates the tran-
scription of the doxorubicin biosynthesis genes. Down 
regulation of doxorubicin is indirected controlled by 
doxR regulator, a gene belonging to the IclR family of 
transcripional regulators, which inhibits the dnrI expres-
sion, leading to blockade of doxorubicin production [26].
Environmental applications
Surfactants are amphipathic molecules with both hydro-
philic and hydrophobic moieties. These properties render 
surfactants capable of reducing surface and interfacial 
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tension and forming microemulsion. Such characteristics 
confer excellent detergency, emulsifying, foaming, and 
dispersing traits; they are the active ingredients found in 
soaps and detergents [27]. Surfactants currently in use 
are chemically derived from petroleum; however, inter-
est in microbial surfactants has been steadily increasing 
in recent years due to their diversity, environmentally 
friendly nature, and their potential applications in the 
environmental protection, crude oil recovery, health care, 
and food-processing industries [28–30]. Biosurfactants 
are biological surface-active compounds largely produced 
by a wide variety of microorganisms, secreted either 
extracellularly or attached to parts of cells, predominantly 
during growth on water-immiscible substrates. Bacteria 
of various genera such as Pseudomonas, Bacillus, Acine-
tobacter, Arthrobacter, and Rhodococcus are able to pro-
duce biosurfactants during hydrocarbon oxidation [31]. 
Biosurfactants have several properties and advantages 
over the chemical surfactants, such as lower toxicity, 
higher biodegradability, better environmental compat-
ibility, higher foaming, high selectivity and specific activ-
ity at extreme temperatures, pH and salinity [28]. 
Biosurfactants are capable of lowering surface and inter-
facial tensions effectively and thus are potential substi-
tutes for widely used chemically synthesized surfactants, 
they have very low critical micelle concentrations (CMC), 
this means that are effective at low concentrations. In 
general, the structure of these molecules includes a 
hydrophobic portion commonly made up of fatty acids 
(saturated, unsaturated, or hydroxylated), whereas the 
hydrophilic portion is usually composed of peptides or 
mono-, di-, or polysaccharides [26]. The major classes 
of biosurfactants include glycolipids, lipopeptides, lipo-
proteins, phospholipids, polysaccharide-lipid complexes, 
hydroxylated and cross-linked fatty acids, and the com-
plete cell surface [27]. One of the potential uses is in the 
oil industry, in which case whole-cell broth could be used 
with minimum purity specification and required in small 
quantities to oil recovery from underground sandstone. 
Another use of biosurfactants is in remediation of hydro-
carbon and crude oil-contaminated soils (Fig.  2b); the 
addition of biosurfactant increase the bioavailability of 
petroleum hydrocarbon pollutants in soil to stimulate the 
indigenous bacterial population to degrade hydrocarbons 
at rates higher [32]. One example is the use of rham-
nolipid biosurfactant from Pseudomona aeruginosa that 
removed oil from contaminated Alaskan gravel from the 
Exxon Valdez oil spill [33]. From studies conducted by 
Urum and Pekdemir [27], it is noted that biosurfactants 
were able to remove significant amount of crude oil from 
contaminated soil, for instance rhamnolipid removed up 
to 80  % oil and lecithin about 42  %. While in the stud-
ies done by Lai et  al. [32], was shown that rhamnolipid 
from P. aeruginosa and surfactin from B. subtillis have 
a higher removal efficiency from a heavy oil-polluted 
site, than the chemicals surfactants Tween 80 and triton 
X-100. In the case of surfactin, has been reported that its 
production has reached concentrations of 10.26 g/L in a 
medium containing starch [34] 2933 times higher than 
that achieved by one report by Ponte Rocha et  al. [35]. 
Rhamnolipid production using P. aeruginosa mutant 
strains grown in blackstrap molasses with or without 
supplementary nitrogen source was of 1.45 g/L after 96 h 
incubation [36]. While Silva et al. [37] using P. aeruginosa 
UCP0992 grown in 100 ml mineral medium (aeration of 
80 %) supplemented with 3 % glycerol and 0.6 % NaNO3, 
as the nitrogen source, at 28  °C after 96  h reached a 
production of 8.0  g/L; similarly Wu et  al. [38] using an 
indigenous strain P. aeruginosa EM1 originating from an 
oil-contaminated site located in southern Taiwan grown 
in inorganic nitrogen (NaNO3) obtained a productiv-
ity of 8.63  g/L. To avoid the inconvenience of working 
with opportunistic pathogen strains like P. aeruginosa, 
attempts have been made to express biosurfactants using 
non-pathogenic strains of bacteria. Wittgens et  al. [39] 
using heterologous expression in Pseudomonas putida 
KT42C1, a strain certified as safety, produced up to 
1.5 g/L of rhamnolipid; while Ochsner et al. [40] reached 
a production of 0.6 g/L in a recombinant P. putida strain 
KT2442. Escherichia coli has also been used to produc-
tion of biosurfactants, as the case reported by Wang 
et al. [41], with the engineered E. coli TnERAB that pro-
duced 65–80 mg/L in MS plus glucose media, and 150–
185 mg/L in LB plus glucose media, respectively.
Human health applications
Since the discovery of penicillin in 1928 by Alexander 
Fleming to 1940, the efforts to produce penicillin have 
conducted the biotechnology sector into a billion dol-
lar industry with deep-tank fermentations at its core 
[42]. The fungi Penicillium chrysogenum is the organism 
utilized to produce penicillin at industrial scale. Peni-
cillins are formed from the amino acids valine, cysteine 
and α-aminoadiapate and include residues such as 
pheniylacetyl [43]. The penicillin biosynthetic pathway 
encompasses δ-(L-α-aminoadipyl)-L-cysteinyl-d-valine 
synthetase (ACVS), isopenicillin N synthase (IPNS), 
isopenicillin N acyl transferase (IAT) and phenylacetyl 
CoA ligase (PCL), with the ACVS belonging to a class 
of NRPSs that exclusively occurs in certain filamentous 
fungi and bacteria (Actinomycetes, Bacilli) [44]. The pro-
duction of penicillin have been reported in bioreactors 
of 100,000  L, achieving 36  g/L at 250  h [42], although 
50  g/L of penicillin can be produced [45]. Therefore, 
the penicillin fermentation process is a good case of a 
development strategy model to follow into a large scale 
Page 5 of 8Martínez‑Núñez and López  Sustain Chem Process  (2016) 4:13 
of nonribosomal peptide process production. However, 
the residual concentrations obtained of many NRP are 
from one to three orders of magnitude below compared 
to that of penicillin. For example, the cyclic undecapep-
tide Cyclosporin A is synthetized by cyclosporine syn-
thetase one of the most complex and largest modular 
enzymes described [46]. Cylcosporine A is produced 
by fungus Tolypocladium inflatum, Beauveria nivea, 
Fusarium roseum, and Tolypocladium niveum and have 
anti-inflammatory, inmunosupressive, antifungal and 
antiparasitic properties [47]. Maximum Cyclosporin A 
production of 1274  mg/L with Tolypocladium inflatum 
was reported by Survase et al. [48] in submerged fermen-
tation. In case of the Echinocandins, novel antymicotics 
produced by ascomycota fungi have a cyclic lipo-hexa-
peptide structure and act as β-1,3-glucan synthase inhibi-
tors [49]. Echinocandin B the precursor of anidulafungin, 
is produced by Aspergillus nidulans and had reached 
1.5  g/L in potato dextrose broth (PDB) [50]. The pneu-
mocandin B0 precursor of caspofungin have reached 
about 2  g/L in the fermentation broth of Glarea lozoy-
ensis [51]. Kanda et  al. [52] reported the screening of a 
mutant of Coleophoma empetri and improved medium 
conditions for production of the antibiotic FR901379, 
the precursor of micafungin. The mutant strain had a 
30-fold higher productivity compared to the wild type 
which produced 1 U/mL. In 2010, Kanda et al. [52] dem-
onstrated the production of FR901379 with optimal con-
ditions in a fermenter of 15,000  l reaching 50 U/mL. In 
the other hand, the bacteria Actinomycetes are known for 
produce novel bioactive compounds; more than 10,000 
compounds were described only from genus Streptomy-
ces [53]. Many of these compounds are synthesized by 
polyketide synthases (PKSs). In case of NRP, bleomycin 
is a glycopeptide produced by Streptomyces verticillus 
with antibacterial and antitumor properties [54] and is 
produced at 10  mg/L [55]. Daptomycin is a lipopeptide 
produced by Streptomyces roseosporus and consist of 13 
aminoacids and have been approved because is effec-
tive for treatment of skin and skin structure infections 
caused by gram-positive pathogens [56]. A production 
of 812  mg/L has been reached through fed-batch fer-
mentation with feedback control of dextrin [57]. In case 
of the peptide antibiotics, bacitracins (Fig.  2a, b) are 
produced by some species of Bacillus licheniformis and 
Bacillus subtilis, in addition contains at least 10 distinct 
dodecapeptides that differ by one or two aminoacids 
[58]. The bacitracin A production has reached approxi-
mately 900 mg/L in cultures of B. licheniformis NCIMB 
8874 with the addition of oligosaccharides as elicitor [59]. 
Polymixns consist of ten amino acids with a character-
istic polycationic heptapeptide ring and an N-terminal 
Fig. 2 Nonribosomal peptides and some applications. a Nonribosomal peptide molecules of surfactin and bacitracin. b Some applications of 
nonribosomal peptides in environmental remediation and human health
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fatty acid modification and are produced by B. subtilis 
and Peanibacillus polymyxa [60]. Although this antibiotic 
is commercial, information about its level of concentra-
tion reached in production is vague. The issues of toxic-
ity of certain NRPs have been described. For example, 
the family of polymixins such as polymyxin B and poly-
myxin E (colistin) that are cyclic lipopeptides produced 
by P. polymyxa were introduced into clinical medicine in 
the late 1950s but its use waned in the 1970s because the 
adverse effects in nephrotoxicity [61–63]. Nonetheless, 
its use has recently increased because the colistin is one 
of the antibiotics used for multidrug-resistant infections 
of Gram-negative bacteria such as P. aeruginosa, Acine-
tobacter baumannii, and Klebsiella pneumoniae [61, 64]. 
Schneditz et  al. [65] reported that the NRP tilivalline 
produced by Klebsiella oxytoca have pathophysiological 
effects on human epithelial cells through the induction 
of apoptosis and disruption of epithelial barrier function. 
Because of the toxicity that can present some NRPs such 
as lipopeptides, efforts have been made to reduce cyto-
toxicity. For example, Jiang and colleagues [66] develop 
a novel class of antibacterial lipopeptides from surfactin 
that have a reduced cytotoxicity with no significant dimi-
nution in antimicrobial activity; another case is the men-
tioned by Robbel and Marahiel [67] with the daptomycin, 
a branched cyclic lipopeptide antibiotic, which was sub-
jected to a deacylation to reduce its cytotoxicity.
Commercial and market opportunities for NRPs
Due to their environment-friendly properties, low tox-
icity and higher biodegradability, the NRPs such as bio-
surfactants have had an increase in their demand for use 
in biotechnological applications, for example, in extrac-
tion of petroleum, environmental restoration, foods, 
beverages, cosmetics, detergents or medicine [68, 69]. 
The total quantity of chemical and biological surfactants 
produced in the US is estimated at more than 10 bil-
lion pounds, and worldwide at 25 billion pounds [70]. 
Regarding only to biosurfactants, the reports for the val-
ues of the world market and its poduction in tonnes var-
ies. Reis et  al. [71] reports that the global market had a 
value of USD 1.7 billion in 2011 and is expected to reach 
USD 2.2 billion in 2018, based on a growth rate of 3.5 % 
per annum, and the global biosurfactants market vol-
ume is expected to reach 476,512.2 tons by 2018. While 
Campos et  al. [72] reports that revenues from the bio-
surfactants market were USD 6.5 billion in 2012, and 
the market volume was 3.5 million tons. But regardless 
of the variation in the reports of market value, both the 
volume and the value of the biosurfantes is increasing. 
Currently the cost of biosurfactants in the market is high, 
compared with chemical surfactants. For example, sur-
factin (98 % purity) from B. subtilis available from Sigma 
Chemical Company has a cost of $191 for a 10 mg vial, 
while the cost of the rhamnolipids (95 % purity) from P. 
aeruginosa is $379 for 10  mg vial; in contrast, chemical 
surfactants as Alkanol® XC (Sigma Chemical Company), 
have a market cost of $72 for 500  g. Although at first 
glance the cost of chemical surfactants is much lower 
than the biosurfactants, due to environmental damage 
that they can cause, eventually their cost is much higher. 
The use of expensive substrates, limited product concen-
trations, low yields and formation of product mixture 
rather than pure compounds, are some reasons for lim-
ited use microbial surfactants and their high cost [73, 74]. 
Despite its high costs, biodegradability and low ecotoxic-
ity of biosurfactants are features that draw the attention 
of companies as Ecover, which is a Belgian manufacturer 
of ecological detergents and cleansing agents, which use 
the biosurfactants sophorolipids in hard surface clean-
ers such as multisurface cleaner, floor soap, and window 
cleaner; or the Japanese company Saraya Co. LTD, which 
commercialized a dish washer containing sophorolipids 
as cleaning agent. Sophorolipids are also used in cosmet-
ics products, for example, the French company Soliance 
produces sophorolipid-based cosmetics for body and 
skin; the Korean MG Intobio Co. Ltd commercializes 
Sopholine cosmetics, which is functional soap specific for 
acne treatment; or the Japanese company Kao Co. Ltd., 
which uses sophorolipids as humectants for cosmetic 
makeup brands such as Sofina [75, 76]. Biosurfactants 
also have been applied in the food industry, for exam-
ple, rhamnolipids can be found as active substance in the 
fungicide Zonix™, produced by the company Jeneil Bio-
tech Inc and approved by FDA for use on vegetables, leg-
umes, and fruits crops [77, 78]. In the medical field there 
are examples of use of NRPs, such as Cyclosporin A and 
bleomycin A2. Cyclosporine A is an immunosuppressive 
agent, which has its application in the aftercare of organ 
transplantations; while bleomycin A2 exhibit cytostatic 
activity, which makes it suitable for cancer therapy [79]. 
These NRPs have high selling prices in the market. The 
cost of these molecules available from Sigma Chemi-
cal Company is $107 for 25 mg of Cyclosporin A (98 % 
purity) extracted from T. inflatum, and $847 for 20 mg of 
bleomycin A2 (70 % purity) extracted from S. verticillus. 
The use of biosurfactants increases, as well as investiga-
tions that result in patents for commercial use [77], but 
still need to reduce their production costs in order to be 
competent in terms of their prices.
Conclusions
Regarding the information of some commercial NRP 
described above, the concentration reached in produc-
tion of them is still poor. Many studies have been made 
of production of NRP that are candidates to be utilized 
Page 7 of 8Martínez‑Núñez and López  Sustain Chem Process  (2016) 4:13 
in different applications. However, its production also is 
deficient. Hence, the bioprocess engineering approaches 
must work together with the approach of bioinformat-
ics genome mining, the heterologous production of NRP, 
the improvement of biosynthetic pathways as well as the 
physiology of the producer cells. Taken examples like 
process development penicillin, we will capable to pro-
duce many NRPs in larger quantities in order to over-
come many problems in human health, crop protection, 
food industry as well as in environmental applications.
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